Reimbursement, regulatory approval, and even who controls the cardiometabolic care budget vary by country. We help you choose the right markets, in the right sequence, and enter each with a model aligned to how its health system actually pays – rather than exporting a US motion that quietly underperforms.
The Challenge
Your whole revenue model is built around US payers and employers
US cardiometabolic companies grow on self-insured employers and commercial health plans. Most of the world does not work that way – single-payer systems, national health services, and out-of-pocket markets each hold the budget in a different place. Exporting a US employer-benefits motion to a country where the government or the patient pays means your go-to-market has no buyer, and companies discover this after they have already staffed the market.
Regulatory and data requirements can block you for a year before your first sale
A diabetes product that is a wellness app in the US may be a regulated medical device in the EU, and cardiometabolic data crosses into strict health-data regimes like GDPR the moment you operate abroad. These are not marketing problems, they are entry gates – and a company that treats international as a growth-marketing exercise gets blindsided by a device classification or a data-residency requirement that stalls launch for quarters.
You chose markets based on size, not winnability
The instinct is to chase the biggest diabetes populations, but population is not the same as accessible, payable demand. A huge market with no reimbursement pathway for digital cardiometabolic care and a fragmented regulatory route can be far harder to win than a smaller market with a clear payer and a friendly approval path. Companies that sequence by raw TAM burn their expansion budget on the market that looks best on a slide and pays worst in reality.
Clinical evidence and outcomes do not automatically transfer
The payer-grade evidence and outcomes story that opens doors in the US may not satisfy a foreign regulator or reimbursement authority that wants local data, local clinical partners, or a different endpoint. Assuming your US evidence base is portable leads to a rejected reimbursement dossier and a scramble to generate local proof after launch – the most expensive possible time to discover the gap.
What We Do
We begin by mapping what truly determines whether a market is winnable: who pays for cardiometabolic care, and how. For every candidate country, we outline the reimbursement structure, whether the buyer is a government body, national insurer, employer, or patient, and what is required to access that budget. This analysis distinguishes markets that merely appear large from those you can actually monetize, and it is the step US companies most often skip on their way to a mistake.
Alongside that work, we assess the regulatory and data gates in parallel – device classification, approval pathway, and market-specific health-data requirements – because in cardiometabolic, these are conditions of entry, not afterthoughts. We identify year-long gates before you allocate headcount, ensuring market selection reflects the true cost and entry timeline rather than a marketing fantasy.
Next, we sequence. Markets are prioritized by winnability – a clear payer, a manageable regulatory pathway, and reachable demand – rather than raw population. The result is an ordered entry plan focused on one or two beachhead markets you can realistically win, instead of stretching a limited expansion budget across five markets that each require a different model.
For the priority market, we build an entry model around how its health system pays – which might require a reimbursement dossier and clinical partnership instead of a demand-gen funnel, or a distributor relationship rather than direct DTC. We tailor the go-to-market to the country rather than imposing your US motion, and identify where local clinical evidence must be developed so it is planned early, not uncovered late.
Our difference is that we are operators creating an executable entry plan tied to your broader growth strategy, not a research firm delivering a country-comparison report. We remain engaged through the initial market entry so the plan evolves with what you learn on the ground, while ensuring international expansion reinforces the core business rather than distracting from it.
What we deliver
- Per-market map of who pays for cardiometabolic care and how to reach that budget
- Regulatory and health-data gate assessment per candidate market
- Winnability-based market sequencing – beachhead first, not biggest first
- Country-fit entry model for the lead market (reimbursement, distributor, or direct)
- Local clinical-evidence plan where US data does not travel
For international cardiometabolic expansion, the best first market is rarely the largest – it is the one with a clear payer and a navigable regulatory route. Winnability beats population every time.
Our Methodology
We deliver a focused engagement that typically lasts 90 days. During days 1-30, we map the reimbursement and regulatory realities across your candidate markets – who pays, how payment works, and which entry gates apply. In days 31-60, we rank markets by winnability and create a country-fit entry model for the lead market, including the local-evidence plan. During days 61-90, we turn that work into an executable entry roadmap with owners, budget, and milestones, then support the first moves on the ground.
Unlike a traditional market-entry consultancy, we start with payment and regulatory realities rather than TAM slides, and develop an entry model suited to the country instead of advising you to copy your US motion. A research firm provides a country-comparison deck; we provide a sequenced plan you can execute, then help you execute it.
The engagement is structured to make you self-sufficient in the lead market. You retain the entry model, sequencing logic, and evidence plan. We would rather help you get the first international market right and leave you with a repeatable method than sell you an open-ended expansion retainer.
Our Approach
The first 30 days are research-heavy and precise – we map reimbursement flows and regulatory gates in every candidate market rather than creating generic country profiles. By the close of month one, you will have target markets ranked by winnability, with each market's payment pathway and entry gates clearly defined.
Our team provides a growth strategist supported by regulatory and market-access research. From your side, we need the leadership team, clinical and regulatory leads, and candor about your willingness to accept the lengthy reimbursement and approval timelines some markets demand. International expansion is a company-level bet, so direct CEO participation produces the best results.
We hold weekly working sessions during mapping and sequencing, then move into entry-plan development and launch support for the final phase. The plan is built alongside your team so the market bet has internal ownership and the tradeoffs – particularly deprioritizing a large but difficult-to-win market – are understood and defensible.
Engagements generally last three to four months, with some extending into hands-on support for the initial market entry. At completion, you have a market sequence ranked by winnability, a country-fit beachhead entry model, and a realistic understanding of the regulatory and evidence work needed before committing.
- Winnability-ranked market sequence
- Country-fit entry model
- Regulatory and data risk surfaced before commitment
- Expansion budget concentrated on a beachhead
If your diabetes & cardiometabolic health company needs international growth leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
What does an international expansion engagement cost for a cardiometabolic company?
The engagement uses a fixed monthly fee over three to four months, priced below a large-firm market-entry study and well below the expense of staffing the wrong first market – the exact mistake this work is designed to avoid. Any extension into hands-on support for the first launch is scoped separately.
When will we begin seeing results from an international expansion engagement?
The strategic deliverables – a market sequence ranked by winnability and an entry model – are completed within the engagement, typically in three to four months. Revenue from a new market comes according to the entry timeline, which can be lengthy in cardiometabolic because reimbursement and regulatory approval are gates that cannot be accelerated.
How does your expansion team work with our current leadership?
Because this is a company-level engagement, we collaborate directly with your CEO as well as your clinical, regulatory, and finance leads. Market selection and entry-model choices are bets that affect the entire company, so we develop them with your team instead of simply delivering a report.
What distinguishes Winston Francois from a conventional market-entry consultancy?
A conventional consultancy ranks markets according to size and delivers a comparison deck. We begin with who truly pays for cardiometabolic care and which regulatory and data gates apply, sequence markets based on winnability, and create a country-fit entry model rather than exporting your US motion.
How do you address regulatory and data requirements across different countries?
For every candidate market, we evaluate device classification, the approval pathway, and health-data requirements alongside the payment analysis, because these are cardiometabolic entry gates that may add a year to launch. Identifying them before headcount is committed ensures market selection accounts for the real cost and timeline. We also highlight where local clinical evidence needs to be generated, allowing it to be planned rather than uncovered after a dossier is rejected. Throughout the process, we coordinate closely with your regulatory lead.
How do you determine which market we should enter first?
We rank potential markets by winnability rather than population – a clear payer for digital cardiometabolic care, a navigable regulatory pathway, and demand you can realistically access. A smaller market with an established reimbursement route often outperforms a massive one where there is no way to get paid. The objective is a beachhead you can win and learn from, enabling your first international revenue to fund the next market entry rather than deplete the core business.
Which type of cardiometabolic company is best suited to this service?
The ideal fit is a growth-stage diabetes or cardiometabolic company with a validated US model and a balance sheet capable of supporting the longer timelines required for international entry. If your US operation is not yet stable or product-market fit remains unresolved, expansion is too early, and we will tell you. The process starts with a call to evaluate whether your model can travel and which markets are realistically accessible.
